Dreams can be powerful, but when combined with action, they become transformative. Sankalp, a visionary with an unwavering belief in the power of persistence, is the perfect blend of dreamer and doer. The Ahmedabad BMT project has been one of our biggest dreams, a vision to elevate the care we provide to children in need of bone marrow transplants. However, turning this dream into reality took more than just hope—it took time, resilience, and unwavering commitment.
Many women in India seek antenatal care late, with 1 in 6 starting after 18 weeks. Sankalp Labs has now secured registration to offer fetal genetic testing for thalassemia and sickle cell diseases, reducing wait times from weeks to just 3 days. This breakthrough enables timely, informed decisions, enhancing prevention program outcomes.
Sankalp Labs is transforming infection diagnostics for bone marrow transplant patients with rapid PCR tests targeting antimicrobial resistance (AMR). These tests detect pathogens within hours, enabling faster, targeted treatments and reducing unnecessary antibiotic use. In December 2024, the lab identified three microbes, marking a significant breakthrough in infection management.
In the last quarter of 2024, thalassemia prevention coordinators from across India took part in a series of valuable training sessions. In Maharashtra, the focus was on building confidence, with role-playing exercises that helped coordinators improve their counseling skills. In Madhya Pradesh, coordinators worked together to align their goals and gained a clearer understanding of thalassemia prevention, enhanced by a visit to the BMT unit.
